Advanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Artzy-Schnirman, ArbelHobi, Nina
Schneider-Daum, Nicole
Guenat, Olivier T
Lehr, Claus-Michael
Sznitman, Josué
Issue Date
2019-09-06
Metadata
Show full item recordAbstract
With rapid advances in micro-fabrication processes and the availability of biologically-relevant lung cells, the development of lung-on-chip platforms is offering novel avenues for more realistic inhalation assays in pharmaceutical research, and thereby an opportunity to depart from traditional in vitro lung assays. As advanced models capturing the cellular pulmonary make-up at an air-liquid interface (ALI), lung-on-chips emulate both morphological features and biological functionality of the airway barrier with the ability to integrate respiratory breathing motions and ensuing tissue strains. Such in vitro systems allow importantly to mimic more realistic physiological respiratory flow conditions, with the opportunity to integrate physically-relevant transport determinants of aerosol inhalation therapy, i.e. recapitulating the pathway from airborne flight to deposition on the airway lumen. In this short opinion, we discuss such points and describe how these attributes are paving new avenues for exploring improved drug carrier designs (e.g. shape, size, etc.) and targeting strategies (e.g. conductive vs. respiratory regions) amongst other. We argue that while technical challenges still lie along the way in rendering in vitro lung-on-chip platforms more widespread across the general pharmaceutical research community, significant momentum is steadily underway in accelerating the prospect of establishing these as in vitro "gold standards"Citation
Eur J Pharm Biopharm. 2019 Sep 6. pii: S0939-6411(19)30785-4. doi: 10.1016/j.ejpb.2019.09.006.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
ElsevierPubMed ID
31499161Type
ArticleLanguage
enISSN
1873-3441ae974a485f413a2113503eed53cd6c53
10.1016/j.ejpb.2019.09.006
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- In situ-Like Aerosol Inhalation Exposure for Cytotoxicity Assessment Using Airway-on-Chips Platforms.
- Authors: Elias-Kirma S, Artzy-Schnirman A, Das P, Heller-Algazi M, Korin N, Sznitman J
- Issue date: 2020
- Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
- Authors: Kolanjiyil AV, Kleinstreuer C, Sadikot RT
- Issue date: 2017 May 1
- In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models.
- Authors: Acosta MF, Muralidharan P, Meenach SA, Hayes D, M-Black S, Mansour HM
- Issue date: 2016
- Does upper airway deformation affect drug deposition?
- Authors: Cheng S, Kourmatzis A, Mekonnen T, Gholizadeh H, Raco J, Chen L, Tang P, Chan HK
- Issue date: 2019 Dec 15
- Clinical perspectives on pulmonary systemic and macromolecular delivery.
- Authors: Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R
- Issue date: 2006 Oct 31